Medical/Pharmaceuticals

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock ...

2022-08-29 15:59 2505

Össur Acquires Naked Prosthetics

HÄMEENLINNA, Finland, Aug. 29, 2022 /PRNewswire/ -- Össur has acquired Naked Prosthetics, a leading provider of durable, custom and functional finger prostheses for finger and partial hand amputees, with effect from26 August 2022 . The mechanical devices are individually designed to mimic the natu...

2022-08-29 15:32 1976

Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress

* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. * Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization. * The novel adjuvants vaccine will create a strong growth engine. TAIZHOU, China, ...

2022-08-29 13:08 3201

Fosun International Listed in Forbes 2022 China ESG 50

HONG KONG, Aug. 29, 2022 /PRNewswire/ -- Forbes China recently released its "2022 China ESG 50" list. Fosun International has been included on the list for its outstanding ESG performance and its active contribution to the fight against the COVID-19 pandemic.Forbes China pointed out that ESG is s...

2022-08-29 12:52 3135

Infinitus co-organizes "Traditional Chinese Medicine Cultural Communication ▪ We are in Action" event

CAE academician Yu Mengsun and Master of traditional Chinese medicine Zhou Daihan visit Infinitus  GUANGZHOU, China, Aug. 27, 2022 /PRNewswire/ -- On August 21, 2022, the Guangdong leg of the "Traditional Chinese Medicine Cultural Communication · We are in Action" event, jointly organized by the...

2022-08-27 09:15 7119

Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization

BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic prod...

2022-08-26 22:09 10760

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform f...

2022-08-26 21:54 9686

Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference

Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration Poster presentations demonstrate synergistic effects of s...

2022-08-26 19:30 2310

VISTA Eye Specialists joins Qualitas Health Family to further strengthen Qualitas' healthcare foothold in Asia Pacific

PETALING JAYA, Malaysia, Aug. 26, 2022 /PRNewswire/ -- VISTA Eye Specialists (VISTA) officially joins the Qualitas Health integrated network of clinics in Asia in a collaboration borne out of the attraction towards values that they share - to provide the Malaysians with access to quality healthcar...

2022-08-26 08:00 3660

Everest Medicines Announces the Departure of CEO, Kerry Blanchard

SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific m...

2022-08-26 07:30 3231

Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan

* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration * Lunit's latest commercial approval to accelerate expansion in the Taiwanese market SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading...

2022-08-25 23:13 3561

Doctors at Manipal Hospitals, Dwarka give new lease of life to a 30-day-old newborn suffering from brain tumor

NEW DELHI and KHARTOUM, Sudan, Aug. 25, 2022 /PRNewswire/ -- Doctors at Manipal Hospitals,Delhi successfully saved the life of a 30-day-old newborn baby with a brain tumor. The baby was presented at the hospital in an emergency with a complaint of seizures and unconsciousness. Upon further diagno...

2022-08-25 21:00 3840

Innovent Announced 2022 Interim Results and Business Updates

* Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutical Companies * Commercial Model and Platform Upgraded to Stage 2.0 * A Robust Pipeline of 34 Valuable Assets Supporting Continuously Growth Momentum ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2022...

2022-08-25 20:06 5175

CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates

SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2022 interim financial results an...

2022-08-25 18:00 4453

Everest Medicines Announces Interim Results for First Half of 2022

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced its interim r...

2022-08-24 21:10 4874

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego

HAMILTON ON, Aug. 24, 2022 /PRNewswire/ -- AtomVie Global Radiopharma Inc. ("AtomVie") today announced the successful closing of its Series A financing with Avego Management, LLC ("Avego"), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Orga...

2022-08-24 21:00 3309

MGI Supports the Ministry of Health of Indonesia in the Country's Breakthrough National Genome Project

JAKARTA, Indonesia, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, today announced that the National Genome Project inIndonesia has selected MGI technology* as one of the technology providers for the first phase of its effort towards establishin...

2022-08-24 17:34 3353

Cancer treatment with the world's smallest rotating gantry began at Yamagata University in 2022: Taking on the challenge of global standardization of heavy ion therapy equipment

SINGAPORE, Aug. 24, 2022 /PRNewswire/ -- In the face of fierce competition among major heavy electric machinery manufacturers, Toshiba deliveredJapan's first rotating gantry for heavy ion cancer therapy using superconducting technology to the National Institutes for Quantum Science and Technology...

2022-08-24 10:00 9078

Mangosteen Peel as Medicine - CU's Faculty of Veterinary Science is Successful in Replicating Mangosteen Peel Extract, Treatment for Intestinal Inflammation in Humans and Animals

BANGKOK, Thailand, Aug. 24, 2022 /PRNewswire/ -- The Faculty of Veterinary Science,Chulalongkorn University has researched and replicated "Hydroxy- xanthones", the vital extracts rich in antioxidants found in mangosteen peels that kill germs and halt infections in the intestinal mucosa. It hopes t...

2022-08-24 10:00 2151

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the ...

2022-08-24 09:00 2654
1 ... 125126127128129130131 ... 382